|Bid||81.15 x 1000|
|Ask||81.15 x 800|
|Day's range||80.88 - 81.48|
|52-week range||68.44 - 84.56|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||36.95|
|Forward dividend & yield||2.60 (3.20%)|
|Ex-dividend date||14 Sep 2021|
|1y target est||N/A|
Earlier this month, Merck (NYSE: MRK) announced it was ending clinical trials of its antiviral pill candidate for treating COVID-19, molnupiravir, on account of the potential therapy's high level of effectiveness. Take Gilead Sciences' (NASDAQ: GILD) antiviral drug, remdesivir. Will Merck's drug follow a similar or better path?
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.